200 related articles for article (PubMed ID: 18476981)
21. Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone.
Shimizu H; Monden T; Nagai T; Shoda Y; Sato T; Yamada M; Mori M
Diabet Med; 2005 Feb; 22(2):225-6. PubMed ID: 15660744
[No Abstract] [Full Text] [Related]
22. Pharmacological treatment of type 2 diabetes.
Hermans MP; Buysschaert M
Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
[No Abstract] [Full Text] [Related]
23. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Polonsky T; Mazzone T; Davidson M
Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
[TBL] [Abstract][Full Text] [Related]
24. Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
Karalliedde J; Viberti GC
Diabetes; 2007 May; 56(5):e3; author reply e4. PubMed ID: 17470560
[No Abstract] [Full Text] [Related]
25. Oral hypoglycemic agents as an alternative therapy for gestational diabetes.
Hod M; Shafrir E
Isr J Med Sci; 1995 Oct; 31(10):640-3. PubMed ID: 7591693
[No Abstract] [Full Text] [Related]
26. [Secondary failure of oral diabetes therapy].
Bergis K; Heilmann B
Fortschr Med; 1987 Feb; 105(4):64-8. PubMed ID: 3557262
[No Abstract] [Full Text] [Related]
27. [PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
Komiyama N
Nihon Rinsho; 2011 Nov; 69 Suppl 9():331-5. PubMed ID: 22724224
[No Abstract] [Full Text] [Related]
28. [Cyclohexamide. A new oral hypoglycemic agent].
Villaseñor A; Parra A; López Amor E; Rull JA; Lozano-Castañeda O
Rev Invest Clin; 1967; 19(2):149-57. PubMed ID: 5317602
[No Abstract] [Full Text] [Related]
29. The new oral antidiabetic drugs.
Moss JM; Delawter DE
Am Fam Physician; 1984 Nov; 30(5):119-21. PubMed ID: 6437197
[No Abstract] [Full Text] [Related]
30. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
31. [Effect of short term hypoglycemic treatment with gliclazide and gliquidone on platelet function in patients with diabetes mellitus type II].
Grzeszczak W; Strojek K
Pol Tyg Lek; 1993 Apr; 48 Suppl 1():38-9. PubMed ID: 8516206
[No Abstract] [Full Text] [Related]
32. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
33. [Limited effect of antidiabetics on type 2 diabetes].
Lindeberg S
Lakartidningen; 1998 Dec; 95(49):5605-6. PubMed ID: 9863297
[No Abstract] [Full Text] [Related]
34. Failure of sulfonylureas in type 2 diabetes.
Yildiz BO; Gürlek A
Horm Metab Res; 1999 Apr; 31(4):293-4. PubMed ID: 10333089
[No Abstract] [Full Text] [Related]
35. [Clinical experience with Glurenorm in type 2 diabetics with renal insufficiency].
Rybka J; Gregorová A; Zmydlená A
Vnitr Lek; 1988 Aug; 34(8):786-92. PubMed ID: 3176368
[No Abstract] [Full Text] [Related]
36. DREAM and ADOPT: rosiglitazone does what it says on the packet.
Bilous R
Diabet Med; 2007 Feb; 24(2):107-9. PubMed ID: 17257270
[No Abstract] [Full Text] [Related]
37. The rosiglitazone controversy: the Indian perspective.
Mohan V; Joshi SR
J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495
[No Abstract] [Full Text] [Related]
38. [Gliquidone--opinions from the international literature].
Krzyzanowska-Swiniarska B; Czekalski S; Fuchs H; Gruszczyńska M
Pol Tyg Lek; 1993 Apr; 48 Suppl 1():40-1. PubMed ID: 8516207
[No Abstract] [Full Text] [Related]
39. Do we need new drugs for the treatment of type 2 diabetes mellitus?
Vervoort G; Tack CJ
Neth J Med; 2007 May; 65(5):157-9. PubMed ID: 17519510
[No Abstract] [Full Text] [Related]
40. Follow-up of intensive glucose control in type 2 diabetes.
Petrie JR
N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
